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Abstract
Background: Multi-drug resistant (MDR) bacteria have become a major concern in hospitals worldwide and urgently require
the development of new antibacterial molecules. Peptide deformylase is an intracellular target now well-recognized for the
design of new antibiotics. The bacterial susceptibility to such a cytoplasmic target primarily depends on the capacity of the
compound to reach and accumulate in the cytosol.
Methodology/Principal Findings: To determine the respective involvement of penetration (influx) and pumping out (efflux)
mechanisms to peptide deformylase inhibitors (PDF-I) activity, the potency of various series was determined using various
genetic contexts (efflux overproducers or efflux-deleted strains) and membrane permeabilizers. Depending on the structure
of the tested molecules, two behaviors could be observed: (i) for actinonin the first PDF-I characterized, the AcrAB efflux
system was the main parameter involved in the bacterial susceptibility, and (ii), for the lastest PDF-Is such as the derivatives
of 2-(5-bromo-1H-indol-3-yl)-N-hydroxyacetamide, the penetration through the membrane was a important limiting step.
Conclusions/Significance: Our results clearly show that the bacterial membrane plays a key role in modulating the
antibacterial activity of PDF-Is. The bacterial susceptibility for these new antibacterial molecules can be improved by two
unrelated ways in MDR strains: by collapsing the Acr efflux activity or by increasing the uptake rate through the bacterial
membrane. The efficiency of the second method is associated with the nature of the compound.
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Introduction
Multi-drug resistance (MDR) in Gram-negative bacteria is
frequently reported in clinical isolates [1,2]. This strongly limits
therapeutic options and is a major cause of mortality in hospital
acquired infections [1–4]. MDR is prevalent in important Gram-
negative clinical pathogens such as Escherichia coli, Salmonella spp.,
Klebsiella spp., Enterobacter spp., and Pseudomonas spp. In these major
pathogens, three major bacterial strategies are involved in the
development of drug resistance: 1) the membrane barrier (acting to
limit the required intracellular dose of an antibiotic), 2) the
enzymatic barrier (producing detoxifying enzymes that degrade or
modify the antibiotic), 3) the target protection barrier (mutation or
expression of a molecule that impairs target recognition and thus
antimicrobial activity) [5]. These Gram-negative bacteria, respon-
sible for a large portion of antibiotic-resistant bacterial diseases,
display a complex cell envelope comprising an outer membrane
and an inner membrane delimiting the periplasm [6]. The outer
membrane contains various protein channels which are involved
in the transport of various compounds including several classes of
antibiotics [6,7]. Bacterial adaptation to reduce the outer
membrane permeability is an increasing problem worldwide,
which contributes, along with efflux systems, to the emergence and
dissemination of antibiotic resistance. Consequently, it is impor-
tant to explore the activity of existing and new antibiotic
compounds by using different bacterial strains harbouring various
resistance backgrounds and in the presence of diverse chemicals
recently described as potent inhibitors of resistance mechanism or
facilitator of antibiotic activity [8–10].
Face to this continuous emerging threat, several novel bacterial
targets have been described as an alternate therapeutic solution to
the emergence and dissemination of MDR bacterial isolates
[11,12]. Peptide deformylase (PDF) is involved in the cleavage of
the N-formyl group of nascent polypeptide. This process is
essential to the growth of bacteria [13] and represents a novel
attractive target for new antibacterial molecules [14–16]. Peptide
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deformylase inhibitors (PDF-Is) have been characterized and
described to be active in various bacterial pathogens. Most of them
such as actinonin, the main characterized inhibitor, are pseudo-
peptidic molecule [17]. Recently we described a new series of
heterocyclic compounds, with an indol scaffold, that inhibit
efficiently bacterial PDF in the nM range [18,19]. Two main
mechanisms mediating resistance to peptide deformylase inhibitors
in bacteria have been previously described. The first is amino acid
substitutions within the target protein (Def) , and the second is the
formylation bypass which results from mutational loss of methionyl
tRNA formyltransferase (Fmt) or of the folD gene [20–22].
However a discrepancy of activity was observed with the efflux
system that seriously compromised the PDF-Is action in some
efflux producing strains [23,24]. The role of AcrB and TolC
component of efflux pump has been reported in the susceptibility
of E. coli and Haemophilus influenzae [18,23,].
The MDR phenotype is often linked to with a general alteration of
membrane properties including a decrease in membrane permeabil-
ity associated with an overexpression of efflux pumps [5]. We decided
to investigate the involvement of the membrane barrier (the ‘‘in and
the out’’ transport) in the activity of some indolic PDF-Is structurally
unrelated to actinonin group (Figure 1) and recently produced
[18,19] in various strains and clinical MDR isolates.
Results
Activity of new PDF-Is and membrane permeability
Actinonin was used as reference molecule to characterize the
antibacterial activities of the newly produced PDF-Is for which an
in vitro activity has been previously reported [19]. In Table 1 were
presented the results obtained on isogenic strains in the absence or
in the presence of various sub-inhibitory concentrations of the
cyclic peptide antibiotic polymyxin B (Pol B) or its derivative the
polymyxin nonapeptide (PMBN) known to increase membrane
permeability [25,26].
In the absence of membrane permeabilizers, we observed a 128
fold decrease of actinonin MIC in the acrAB deleted strain
compared to the parental ones. This suggests that AcrB pump is
directly involved in the resistance observed in the parental strain
towards this molecule. Regarding the other PDF-Is, we did not
observed a susceptibility level similar to that obtained with
actinonin. These results indicate that SM1, SM2, and AB47
compounds are not recognized as specific substrate for AcrAB
efflux transporter or that another rate-limiting step is involved.
Concerning SM3, whatever the tested strains or the conditions
used, no antibacterial activity was detected (data not shown).
The effect of membrane permeabilizer, e.g. Pol B and PMBN,
was assayed on the PDF-Is activities. The MICs for Pol B and
PMBN were determined for each bacterial strain. From the
respective MICs, a sub-inhibitory amount (MIC/5 and MIC/10)
was added in the presence of each PDF-I. For actinonin, the
presence of PMBN induced a serious decrease of MIC to the
susceptible level whatever the strain tested. In the acrAB deleted
strain, a small increase of susceptibility was noted (MIC of
0.25 mg/ml). Concerning the other molecules, the addition of
PMBN, and Pol B at a lesser extent, induced a noticeable increase
of susceptibility (Table 1). It is interesting to note that for SM1,
SM2 and AB-47 whatever the strain background tested an
important MIC decrease was induced in the presence of PMBN.
Concerning SM3, no increase in the susceptibility was observed in
Figure 1. Structures of PDF-Is used.
doi:10.1371/journal.pone.0006443.g001
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the acrAB deleted strain in the absence or in presence of PMBN
(data not shown). In addition, in the same conditions, presence of
Pol B or PMBN, only a very limited effect was noted on the
activity of usual antibiotics such as norfloxacin and chloramphen-
icol (Table 1).
The activity of the different PDF-Is was tested on other Gram-
negative bacteria involved in human infectious diseases such as
Pseudomonas aeruginosa, Enterobacter aerogenes and Klebsiella pneumoniae
(Table 2). SM1 and actinonin exhibited no antibacterial activity on
the P. aeruginosa strains including reference strain PA01 and clinical
isolate 124. The addition of PMBN during the incubation
noticeably increased the activity of actinonin, AB-47, SM1
(Table 2). A less efficient effect was obtained with SM2 (data not
shown). It is interesting to note that the level of resistance for the P.
aeruginosa clinical isolate (124 in table 2) which is a MDR strain with
several mechanisms including efflux pump overexpression, was
more significant for usual antibiotics (norfloxacin, tetracycline, etc).
We observed similar profiles with other Gram-negative
bacterial pathogens and the activity of actinonin was noticeably
increased in the presence of membrane permeabilizer. The
tested clinical MDR isolates (E. aerogenes EA5 and EA27; K.
pneumoniae KP55 and KP63) exhibited a lower susceptibity
towards other PDF-Is assayed under the same conditions.
Moreover, in the derivative strains of MDR E. aerogenes clinical
isolate EA27, we observed a significant role of the efflux pump:
when the tolC or acrAB genes were knocked out, the presence of
PMBN induced a noticeable increase of actinonin and SM1
activity, e.g. compare EA289 and EA298 strains in Table 2.
Under these conditions, it is worthy of note that the tolC deletion
was more efficient compare to acrA for actinonin (MICs of 0.5
and 2 respectively). A similar level was reached in the two acrA
and tolC deleted strains for SM1 and AB47 (8 and 16, 16 and 32
respectively). It has been previously demonstrated that at least
two distinct efflux pumps are active, AcrAB-TolC and another
unidentified pump, in the EA27 clinical isolate and its EA289
derivative strain [27]. In these MDR isolates, the results
indicated that the AcrAB-TolC could be the main transporter
involved for actinonin efflux. By contrast, regarding SM1 and
Table 1. Determination of antibacterial activity of various PDF-Is on E. coli strains.
Strains
Actinonin MIC
(mg/ml)
AB47 MIC
(mg/ml)
SM1 MIC
(mg/ml)
SM2 MIC
(mg/ml)
Norfloxacin MIC
(mg/ml)
Chloramphenicol
MIC (mg/ml)
Permeaa 0 PMBNb Pol Bc 0 PMBNa Pol Bb 0 PMBNa Pol Bb 0 PMBNa Pol Bb 0 PMBNa Pol Bb 0 PMBNa Pol Bb
AG100 128 2 (4) 16
(128)
512 8
(32)
64
(128)
.512 4 (8) .128
(.128)
.512 8 (16) 128
(.128)
0.25 0.125 0.125 8 2 4
AG102 128 16 128 512 32 128 .512 16 .128 .512 16 128 1 0.5 1 16 16 16
AG100A 1 0.125
(0.25)
0.25
(0.25)
64 16
(16)
32
(32)
128 4 (4) 16 (32) 64 8 (8) 32 (32) 0.06 0.06 0.03 1 1 0.5
AG100Atet 512 16 .128 256 16 16 .512 16 .128 .512 8 .128 1 0.5 1 64 32 64
Values are means of four independent assays.
apermeabilizer used.
bPMBN was used at 1/5 MIC, in bracket the results with 1/10 MIC are indicated.
cPol B was used at 1/5 MIC, in bracket the results with 1/10 MIC are indicated.
doi:10.1371/journal.pone.0006443.t001
Table 2. Activity of PDF-Is on MDR Gram-negative isolates.
P. aeruginosa E. aerogenes K. pneumoniae
PA01 124
ATCC
13048 EA5 EA27 EA289 EA298 EA294
ATCC
11296 KP55 KP63
Actinonin 128 128 .128 128 128 .128 32 128 128 128 128/64
Actinonin + PMBN a 4 16 8 64 64 32 0.5 2 32 32 32
SM1 128 128 .128 .128 .128 .128 64 128 .128 .128 128
SM1 + PMBN a 2 8 8 32 32 32 8 16 64 64 128–64
AB47 128 .128 .128 .128 .128 256 128 128 128 128 128
AB47 + PMBN a 4 8 32 128 128 128 16 32 64 64 64–32
CM 256 256 8 .128 .128 .128 32 (16) b 32 16 (4) b 256 .512
NFX 2 64 0,5 128 128 128 16 (32) b 32 1 (0.5) b 16 8
CAZ 8 32 1 .512 .512 .512 .512 .512 1 .512 .512
ERY 1024 1024 512 512 512 512 32 128 128 512 512
TC 16 64 4 4 16 8 0.5(0.25) b 1 2 (2) b .128 8
Values are means of four independent assays listed in mg/ml.
CM, chloramphenicol; NFX, norfloxacin; CAZ, ceftazidime; ERY, erythromycin; TC, tetracycline.
aPMBN was used at 1/5 MIC.
bin bracket the results obtained with 1/5 PMBN are indicated.
doi:10.1371/journal.pone.0006443.t002
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AB-47, additional pump may also modulate the activity of these
molecules since in EA298 with PMBN the MICs was 8 and 16
compare to actinonin MIC (0.5). It is interesting to note that, in
general,the new antibacterial molecules tested here seemed to
be more efficient against clinical isolates compare to several
hospital-used antibiotics (e.g., erythromycin, ceftazidime).
Effect of efflux pump inhibitors on PDF-Is activity
The impact of efflux pumps in antibiotic susceptibility has been
largely demonstrated [28–30]. The results shown in Table 1
suggested an involvement of AcrAB pump in the actinonin efflux
and at lesser extent for the other tested PDF-Is. In this context, to
get more insight in the process we determine the effect of a well-
described efflux pump inhibitor, PAbN which is able to block the
activity of various efflux pumps in addition to AcrAB-TolC [8,9].
In Table 3, the results indicated that the PAbN induced only a
limited increase of PDF-Is activities compared to PMBN.
Moreover, when the two molecules, PMBN and PAbN, were
conjointly added no cumulative effect was observed (data not
shown). Since AcrAB was involved in modulating actinonin
activity, these results suggest that PAbN was not an effective
competitive substrate for efflux of PDF-Is. In other words, the
affinity constant of efflux pump for PDF-Is may be stronger
compare to PAbN.
Same results were obtained when the assays were performed on
P. aeruginosa strain (Table 3). We have similarly determined the
effect of other inhibitors such as reserpine, verapamil and
omeprazol. No significant change in the MICs of PDF-Is was
obtained in the various E. coli strains (data not shown).
Activity of PDF-Is on lipopolysaccharide (LPS) deep rough
mutants, effect of detergents and chelators
In Gram negative bacteria, the LPS constitutes the outer leaflet
of outer membrane and may impair the penetration of
antibacterial agents [6]. Since we have observed that the addition
of membrane permeabilizer such as Pol B or PMBN, are capable
to induce a serious decrease of MICs, we tested a series of
Salmonella typhimurium LT2 mutants producing truncated LPS
[31] to assess a putative role of LPS structure in the PDF-Is
activity. These strains have been previously used as standard
strains to assess the role of LPS on the level of diffusion through
the outer membrane [31]. As shown in Figure 2, the actinonin
activity was increased by 8 fold in LPS truncated mutants while
only 2.5 fold activity increased was observed with other
compounds. By contrast, in the presence of PMBN, we observed
an effective restoration of susceptibility and a quite similar MIC
was obtained for actinonin, AB47 and SM1. This suggests that the
truncated LPS increased the bacterial susceptibility to actinonin
probably by facilitating the diffusion through the LPS layer of
outer membrane. Regarding the activity of the other molecules,
the presence of LPS barrier is not the limiting step since PMBN
addition was required to reach the same level of antibacterial
activity.
An alternate way to bypass the membrane barrier is to use
chaotropic agents or detergents [6]. The assays with actinonin and
SM1 were carried out on E. coli AG100 in the presence of a
chelator agent such as EDTA or in the presence of various
detergents including SDS, DOC or Tx-100. Interestingly, no
significant effect was observed except in the case of actinonin and
EDTA for which the activity is noticeably increased: a decrease of
64 fold was obtained for actinonin MIC (Table 4). These results
fitted well with the results of Figure 2 that indicated a role for LPS
in the actinonin activity.
Discussion
The worldwide dissemination of « pandrug » and « multidrug»
resistant pathogens have severely compromised the efficacy of our
antibiotics and dramatically increased the occurence of therapeu-
tic failure [3,4,32]. To efficiently combat multi-resistant patho-
gens, it is urgently require to define new targets and to produce
novel classes of antibiotics. Several new potent antibacterial
molecules have been recently tested and among them, the PDF-I
group presents attractive properties including a novel and specific
bacterial target and mode of action [13,33].
In this antibacterial group, new derivatives of 2-(5-bromo-1H-
indol-3-yl)-N-hydroxyacetamide have been recently described
[18,19]. It is important to define the activity of these compounds
taking into account the bacterial adaptation to antibacterial
agents. The special architecture of Gram-negative envelope
screens the enter of molecules and strongly control the diffusion
of toxic molecules including antibiotics, detergents, etc [6,7,31].
The outer membrane comprising a lipid bilayer that is
impermeable to large and charged molecules, is the first barrier
against toxic compounds [5,6]. Moreover, efflux mechanisms also
control the intracellular concentration of compounds [5,30].
Consequently, the bacterial susceptibility to PDF-Is is assayed in
various genetic and culture conditions modifying the membrane
permeability.
When the molecules are assayed on isogenic strains expressing
various level of AcrAB efflux pump, it is observed that actinonin is
a substrate for AcrB efflux transporter: the acrAB deleted strain
exhibits a noticeable susceptibility to actinonin in contrast to other
PDF-Is. However, actinonin is also recognized by other RND
efflux system including AcrD, AcrF, etc. These pumps are
overexpressed in the tetracycline induced acrAB deleted strain
[34] and the MIC for actinonin is strongly increased. Interestingly,
the efflux pump inhibitor used, PAbN, which is able to restore
susceptibility to several usual antibiotic family in various
Table 3. Effect of efflux pump inhibitors and membrane
permeabilizers.
Bacteria Actinonin AB47
E. coli 0 PMBNa PAbN 0 PMBNa PAbN
AG100 128 2 32 512 8 128
AG102 128 16 64 512 32 128
AG100A 1 0.125 0.5 64 16 16
AG100Atet 512 8 32 256 16 128
P. aeruginosa
124 128 16 32 .128 8 128
SM1 SM2
E. coli 0 PMBNa PAbN 0 PMBNa PAbN
AG100 .512 4 128 .512 8 128
AG102 .512 4 128 .512 16 128
AG100A 128 4 16 64 8 32
AG100Atet .512 16 64 .512 8 64
P. aeruginosa
124 128 8 128 .128 64 32
Values are means of four independent assays.
aPMBN was used at 1/5 MIC.
bPAbN was used at 20 mg/ml.
doi:10.1371/journal.pone.0006443.t003
PDF-I and Bacterial Membrane
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enterobacteriaceae [8,9], has no strong effect on the level of PDF-Is
susceptibility. The MICs are only reduced in the strain
overproducing efflux pumps different to AcrAB suggesting that
these efflux transporters are involved, partially, in the PDF-Is
resistance. These data suggest that actinonin and PAbN do not
share the same affinity sites in the efflux pump cavities as
previously mentioned for certain pump substrates [35–37].
Regarding the respective susceptibility of the various strains which
produce different levels and types of documented efflux pumps
[34,35], the tested efflux mechanisms seems to be not the main
and sole process involved in the lack of activity of PDF-Is, with the
exception of the involvement of AcrAB in actinonin activity. The
difference in the chemical structure of the various molecules
(Figure 1) may support these discrepancies in the recognition and
transport by efflux pumps observed here. It is interesting to
mention that actinonin seems to be an effective substrate for
AcrAB-TolC compare to SM1, SM2 and AB47. These results
obtained with the tolC deleted MDR isolate (EA298) confirm the
involvement of a TolC-dependent channel which has been
previously noted [18], associated with the expression of the AcrB
family (e.g. AcrD, AcrF, etc) in the bacterial susceptibility to
actinonin.
Influx or penetration represents the other aspect of membrane
role in controlling molecule uptake [5]. Recent studies have
evidenced that PMBN, a cationic peptide that perturbs the outer
membrane, is able to increase the rifampin susceptibility in
resistant strains [38]. Studies of PMBN mode of action against
Gram-negative bacterial cells have shown that bacterial
Figure 2. Activity of PDF-Is on Salmonella wild-type strain SL696 and its LPS-deficient mutants. Various isogenic strains, WT (intact LPS),
Rc (truncated LPS: lipidA-KDO-hep-hep-Glc) and Re (truncated LPS: lipidA-KDO) previously described [31] were used. Act-Control, actinonin alone;
Act-PMBN, actinonin + PMBN; AB47-Control, AB47 alone; AB47-PMBN, AB47 + PMBN; SM1-Control, SM1 alone; SM1-PMBN, SM1 + PMBN; SM2-Control,
SM2 alone; SM2-PMBN, SM2 + PMBN. PMBN was used at 1/5 MIC. MIC values are in mg/ml.
doi:10.1371/journal.pone.0006443.g002
Table 4. Effect of EDTA and detergents on PDF-Is activity.
E. coli strain Actinonin SM1
0 SDS Tx-100 DOC EDTA 0 SDS Tx-100 DOC EDTA
AG100 128 128 128 64 2 .128 .128 .128 .128 .128
Values are means of four independent assays.
The different compounds were used at concentration for which no direct antibacterial effect was observed. EDTA was used at 1 mM ; SDS at 100 mg/ml; Tx-100 at
1000 mg/ml; DOC at 1000 mg/ml.
doi:10.1371/journal.pone.0006443.t004
PDF-I and Bacterial Membrane
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membranes are the primary target : PMBN exhibits the ability of
polymyxins to disrupt or disorganise the cell envelope but fails to
kill the cells at low concentrations [25,38]. The PMBN
treatment shows an increase in the permeability of the E. coli
membrane. At sub-inhibitory concentration, PMBN promotes
an increase of PDF-Is susceptibility whatever the compound
(actinonin, AB47, SM1, SM2) or the bacteria tested (E. coli, P.
aeruginosa, etc). This improvement of PDF-Is activity is also
observed when the bacteria overproduce efflux pumps (AcrB or
other pumps) demonstrating that the influx/diffusion through
the membrane is a limiting step for the AB47, SM1 and SM2
antibacterial activity. It is worthy of note that AB47, SM1 and
SM2 exhibited a same core structure with aromatic rings, a
structure different from that of actinonin (Figure 1). In addition,
we observed a noticeable decrease of MICs for actinonin, SM1
and SM2, and at less extent with AB47 in the acrAB deleted
strain treated by PMBN. The comparison with usual antibiotics
tested under the same conditions indicates that penetration is the
key step for AB47, SM1 and SM2. A similar result was obtained
with other Gram-negative bacteria including P. aeruginosa, K.
pneumoniae and E. aerogenes.
The addition of sub-inhibitory concentration of PMBN facilitates
the penetration of these molecules and partially counterbalances the
activity of efflux pumps. The use of polymyxins, alone or in
combination with other antibiotic classes has been recently
questionated due to the increase of infectious disease caused by
MDR pathogens [11,26,39]. In this study, it is important to mention
that low concentration of Pol B and PMBN (1/5 and 1/10 MICs)
facilitates the activity of PDF-Is. This facilitator effect indicates that
these new antibacterial agents probably not used the porin to enter
the cell as reported for b-lactams and fluoroquinolones [6,7], but a
diffusion pathway through the lipid bilayer. The use of several
isogenic strains previously selected for membrane permeability
studies [31] indicate that LPS truncated mutants are more sensitive
to actinonin than the wild type parental strain. This result fits well
with the increase of actinonin susceptibility observed in the presence
of EDTA, a potent cationic chelator which affects the LPS
organization [6,38]. Thus, the diffusion through LPS layer, in
addition to efflux pump is important for actinonin activity. In
contrast, for the other PDF-Is which exhibit different chemical
structure, the modification of LPS (viamutation, or EDTA addition)
did not improve the activity.
To conclude, two processes are able to modulate the
antibacterial activity of the new molecules tested and their
respective involvement seems to be related to their structure.
The level of actinonin susceptibility is controlled mainly by the
efflux pump expression, the AcrAB-TolC system playing a central
role in pumping the molecule out of the bacterial cell. The LPS
may be partially involved in the uptake pathway of actinonin
through the outer membrane. In contrast, the other tested
molecules are more dependent on the permeation rate and PMBN
appears as an efficient adjuvant to ensure a correct internal
concentration. Concerning the molecules tested here in the
presence of membrane permeabilizer, SM1 exhibits a level of
activity quite similar to that observed with actinonin.
It is interesting to mention that during this work, we have
been able to enhance the antibacterial activity of these
molecules by two independent ways, firstly by eliminating the
Acr efflux transporters, secondly by increasing the uptake rate
through bacterial membrane. In the case of actinonin, this
indicates that we can balance the activity of efflux pump by
increasing the penetration rate. In the case of other compounds,
we can bypass the limited diffusion by increasing the membrane
permeability.
Materials and Methods
Bacterial Strains
The various strains are presented in Table 5. Briefly, Escherichia
coli K-12 AG100 strain (argE3 thi-1 rpsL xyl mtl delta (gal-uvrB)
supE44), AG100A, AG102 and AG100Atet derivatives have been
characterized [34,35]. Salmonella enterica Typhimurium strains,
SL696 WT, SL1069 Rc, SL1102 Re which produce different types
of lipopolysaccharide (LPS) have been characterized [31].
Pseudomonas aeruginosa strains are PA01(ATCC) and the clinical
isolate 124 [43] Enterobacter aerogenes ATCC 13048 and clinical
resistant isolates EA5, EA27, KP55 and KP63 have been
previously described [40,42].
Chemicals
PDF-Is used were : Actinonin (Sigma), AB-47, SM1, SM2 and
SM3were previously described and characterized [18,19] (Figure 1).
Phenylalanine arginine b-naphthylamide (PAbN), reserpine, verap-
amil were assayed as efflux pump inhibitors [34,44] and
norfloxacin, tetracycline and chloramphenicol were used as
reference antibiotics. Polymyxin B (Pol B) was used as membrane
permeabilizer in addition to polymyxin B nonapeptide (PMBN), a
cationic peptide that perturbs the outer membrane bilayer without
the killing action of unmodified polymyxin [25,26]. EDTA was used
to produce divalent cation-poor growth conditions [38]. SDS, DOC
and Triton X-100 were used as detergents.
Table 5. Bacterial strains used in this study.
Bacterial strains Major characteristics Origin
Escherichia coli
AG100 argE3 thi-1 rpsL xyl mtldelta
(gal-uvrB) supE44
34
AG100A AG100 D acrAB:: Kanr 34
AG102 AG100 overproducing AcrAB 35
AG100Atet AG100Atet, AG100A selected
on tetracycline
34
Enterobacter aerogenes
ATCC13048 ATCC strain 40
EA5 MDR clinical isolate 40
EA27 MDR clinical isolate 40,41
EA289 Kans derivative of EA27 41
EA298 EAEP289 tolC:: Kanr 41
EA294 EAEP289 acrA::Kanr 41
Klebsiella pneumoniae
ATCC11296 ATCC strain 42
KP55 MDR clinical isolate 42
KP63 MDR clinical isolate 42
Pseudomonas aeruginosa
PA01 ATCC strain 43
124 MDR clinical isolate 43
Salmonella enterica
Typhimurium
(LT2)
SL696 WT, metA22, trpB2, strAi20 31
SL1069 SL696 Re derivative 31
SL1102 SL696 Re derivative 31
doi:10.1371/journal.pone.0006443.t005
PDF-I and Bacterial Membrane
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Antibiotic susceptibility tests
Bacteria were grown in Mueller–Hinton (MH) broth at 37uC.
Susceptibilities to antibiotic compounds (polymyxin B, PMBN,
norfloxacin, ceftazidime, tetracycline and chloramphenicol) and
efflux inhibitors (PAbN, reserpine, verapamil) were determined by
broth dilution method, as previously described [40,44] Minimal
inhibitory concentrations (MICs) were determined with an
inoculum of 106 CFU in 1 mL of MH broth containing two-fold
serial dilutions of each antibiotic. Isolates were classified as
susceptible, intermediately susceptible or resistant to the antibiotics
tested according to the Antibiogram Committee of the French
Society for Microbiology [45].
Effect of membrane permeabilizers and efflux pump
inhibitors
The efflux pump inhibitor (EPI) PAbN was used as previously
reported: MICs of each antibiotic were determined in the presence
of PAbN at a concentration which has no effect on bacterial cells
[44].To evaluate a possible role of efflux or membrane barrier in
the PDF-Is activity, we developed an in vitro assay using different
conditions: PDF-Is alone, PDF-Is + polymyxin (at 1/10 or 1/5
MIC), PDF-Is + EPI (PAbN or other EPIs), and PDF-Is +
polymyxin + EPI. Norfloxacin and chloramphenicol belonging to
unrelated structural antibiotic groups were used as internal
standard. The results were scored after 18 h at 37uC and were
expressed as mg/ml (MIC).
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